Authors
Latest:
Stephanie Cherqui, PhD, on Bringing Attention to Cystinosis and Gene TherapyThe associate professor from UC San Diego discussed promising efficacy and safety data from a phase 1/2 trial.
Latest:
Genovefa (Zenia) Papanicolaou, MD, on Managing Infectious Diseases in Patients Receiving Stem Cell Transplant or Cell TherapyThe infectious diseases specialist at Memorial Sloan Kettering Cancer Center discussed the session she chaired for the Infectious Diseases Track at Tandem’s 2024 Meeting.
Latest:
BASECAMP-1 Trial Identifies Patients With Solid Tumors to Assess Novel CAR T-Cell TherapyJ. Randolph Hecht, MD, discusses the challenges researchers have faced in the development of cellular therapy for patients with solid tumors, and details how A2B530 could potentially overcome some of these obstacles.
Latest:
Dilsher Dhoot, MD, on a Promising Start With Diabetic Retinopathy Gene Therapy RGX-314The adjunct clinical assistant professor, ophthalmology, Keck School of Medicine, University of Southern California discussed new data from the ALTITTUDE trial.
Latest:
Sickle Cell Disease Gene Therapy Exa-Cel's Ability to Prevent VOCsHaydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial, discussed the latest data update from the CLIMB SCD-121 trial evaluating exa-cel.
Latest:
Robert J. Hariri, MD, PhD, on the Unique Potential of Chimeric TherapyThe founder, chairman, and CEO of Celularity shared his view on the concept of “chimeric vigor” and the potential benefits arising from it in the cell therapy field.
Latest:
Weijia Fang, MD, and Guoqiang Ai, MD, on the Future of IMC001 in Gastric and Colorectal CancerFang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.
Latest:
Faraz Ali, MBA, on Trends in Precision Medicine for Cardiovascular DiseaseThe chief executive officer of Tenaya Therapeutics discussed the growing interest in genomic medicines in cardiology.
Latest:
The Power of Partnership in CMT Gene Therapy ResearchSusan Ruediger, founder and chief mission officer, CMT Research Foundation, discussed the origins of the CMTRF.
Latest:
Michael Severino on In Vivo Gene Editing With RNA Gene WritersThe chief executive officer of Tessera Therapeutics discussed ongoing research into developing its platform for sickle cell disease, CAR T-cell therapy, and more.
Latest:
Alfred L. Garfall, MD, MS, on Ide-Cel and Lenalidomide Maintenance in MM Following Suboptimal ASCT ResponseThe director of the Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program at the Hospital of the University of Pennsylvania discussed data from the phase 2 BMT CTN 1902 trial.
Latest:
Ami J. Shah, MD, on Reaching Normalized Hemoglobin With Gene-Edited Cell Therapy in PKDThe clinical professor of pediatrics at Stanford Medicine discussed positive interim findings from a phase 1 study of RP-L301.
Latest:
Selecting Cell Therapy Targets in CancerThe chief executive and medical officers of Cytovia Therapeutics discussed the company's therapeutic targets and cell therapy scaffold.
Latest:
Vlad Hogenhuis, MD, MBA, on Developing Controllable CAR Ts for Solid TumorsThe chief executive officer of Chimera Bioengineering discussed CBIO-007 and its planned IND submission for colorectal and triple negative breast cancer.
Latest:
Brett Kopelan, MA, on the Future Treatment of Epidermolysis Bullosa With Advanced TherapeuticsIn observance of Epidermolysis Bullosa Awareness Week, the executive director of debra of America discussed how a combination of advanced and topical approaches may represent the future of EB treatment.
Latest:
Dr. Anderson on Addressing Unmet Needs in Myeloma With Descartes-11Kenneth C. Anderson, MD, discusses potentially addressing unmet needs in patients with multiple myeloma through the use of the mRNA-based CAR T-cell therapy Descartes-11.
Latest:
Jason Fontenot, PhD, on Overcoming the Challenge of Delivery for Zinc Finger Epigenetic RepressorsThe chief scientific officer of Sangamo Therapeutics discussed the company’s AAV capsid evolution research.
Latest:
As Gene Editing Technology Advances, Numerous Potential Modalities EmergeJanice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences, discussed the importance of diverse approaches to gene editing to address a variety of indications.
Latest:
CARsgen Therapeutics’ CT041 Shows Promise in Advanced Gastric/Gastroesophageal Junction AdenocarcinomaThe chimeric antigen receptor-modified autologous T cells targeting CLDN18.2 had a manageable safety/tolerability profile and promising efficacy.
Latest:
Addressing Unmet Needs With Gene TherapyEric Crombez, PhD, senior vice president and chief medical officer of Ultragenyx Gene Therapy, discussed indications the company is targeting.
Latest:
Aimee Donald, MBChB, PhD, on Making Progress With Gene Therapy in Lysosomal Storage DiseasesThe pediatrician from Royal Manchester Children’s Hospital discussed how further research in Gaucher disease can benefit the field of rare lysosomal diseases as a whole.
Latest:
Assessing Efficacy of Fibroblast Cell Therapy in MS: Hamid Khoja, PhDThe chief scientific officer of FibroBiologics discussed efficacy findings from a phase 1/2 trial.
Latest:
Selecting Cell Therapy Targets in CancerThe chief executive and medical officers of Cytovia Therapeutics discussed the company's therapeutic targets and cell therapy scaffold.
Latest:
Donald Kohn, MD, on the Trajectory of Gene TherapyThe renowned professor from University of California Los Angeles reflected on receiving the Outstanding Achievement Award from the ASGCT.
Latest:
Continuing the Marathon of Muscular Dystrophy ResearchJeffrey Chamberlain, PhD, McCaw Endowed Chair of Muscular Dystrophy at University of Washington, shared his outlook on the trajectory of research in the field.
Latest:
Pamela Garzone, PhD, on Exploring Unknowns in CAR-T for Solid TumorsThe chief development officer of Anixa Biosciences discussed the company’s trial of a CAR-T in ovarian cancer that is looking at the effect of regional administration and lymphodepletion on efficacy.
Latest:
Alexandra Gomez-Arteaga, MD, on Expanding Eligibility for Cell Transplant With Cell TherapyThe Assistant Professor of Medicine at Weill Cornell Medical College discussed the changing cell transplant landscape.
Latest:
Challenges With Conducting Clinical Trials in Gaucher Disease: Neil Weinreb, MDThe chair of the International Collaborative Gaucher Group Registry discussed challenges in Gaucher research.
Latest:
CGTLive’s Weekly Rewind – April 8, 2022Review top news and interview highlights from the week ending April 8, 2022.
Latest:
Developing Controllable Tumor Infiltrating Lymphocyte TherapiesJan ter Meulen, MD, PhD, chief scientific officer, Obsidian Therapeutics, discussed the potential of the cytoDRIVE platform.
